Medical care for patients with chronic skin diseases by an app-based solution using contact-less diagnostics

Medical care for patients with chronic skin diseases by an app-based solution using contact-less diagnostics - HybridVITA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033790

Enrollment

Registered

2025-04-02

Start date

2024-02-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40.0 L40.5

Interventions

Group 1: Over a one-year observation period, the participants will be examined during three study visits (at baseline, 24 weeks, and 52 weeks after study inclusion). Data on their personality, disease

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - psoriasis vulgaris confirmed bei dermatologists - initial diagnosis of psoriasis at least one year ago - at least three documentable psoriasis plaques on the body - ability to consent

Exclusion criteria

Exclusion criteria: - inability to consent - age under 18 years - not owning a smartphone or not having access to a smartphone

Design outcomes

Primary

Measure	Time frame
1. Psoriasis plaques can be reliably segmented using an artificial intelligence (AI)-supported analysis of the texture, perfusion and redness of the skin via an app. 2. The AI ??and AutoML-based image analyses allow a reliable prediction of new disease flare-ups (deterioration of 20% of the initial value). 3. Significant reduction in the number of hospital stays and personal doctor/patient contacts compared to the year before inclusion in the study.	—

Measure

Time frame

1. Psoriasis plaques can be reliably segmented using an artificial intelligence (AI)-supported analysis of the texture, perfusion and redness of the skin via an app. 2. The AI ??and AutoML-based image analyses allow a reliable prediction of new disease flare-ups (deterioration of 20% of the initial value). 3. Significant reduction in the number of hospital stays and personal doctor/patient contacts compared to the year before inclusion in the study.

—

Secondary

Measure	Time frame
1. The use of such a hybrid app for patients with psoriasis results in secondary and tertiary cost savings. 2. An escalable, multi-stage, multimodal interaction process (information/coaching offer with chatbot, video-based questionnaires to assess the patient's psychological stress, as well as direct communication with the doctor) leads to a significant reduction in psychological stress in psoriasis patients. 3. The Psoriasis Area and Severity Index (PASI) can be reliably recorded digitally using a tactile interface (sensory glove). 4. Using the interventions presented here, PASI can be reduced by at least 20%. 5. Using the interventions presented here, pain can be reduced by at least 20% of the initial value. 6. Evaluation of the app by the patients using free text and multiple choice questions and MARS (medication adherence report scale). 7. Basis for decision on the feasibility of a future clinical study for the approval of the app as a type IIb medical device.	—

Measure

Time frame

1. The use of such a hybrid app for patients with psoriasis results in secondary and tertiary cost savings. 2. An escalable, multi-stage, multimodal interaction process (information/coaching offer with chatbot, video-based questionnaires to assess the patient's psychological stress, as well as direct communication with the doctor) leads to a significant reduction in psychological stress in psoriasis patients. 3. The Psoriasis Area and Severity Index (PASI) can be reliably recorded digitally using a tactile interface (sensory glove). 4. Using the interventions presented here, PASI can be reduced by at least 20%. 5. Using the interventions presented here, pain can be reduced by at least 20% of the initial value. 6. Evaluation of the app by the patients using free text and multiple choice questions and MARS (medication adherence report scale). 7. Basis for decision on the feasibility of a future clinical study for the approval of the app as a type IIb medical device.

—

Countries

Germany

Contacts

Public ContactAstrid Schmieder

Universitätsklinikum Würzburg, Klinik für Dermatologie, Venerologie und Allergologie

schmieder_a@UKW.de+49 176 55000878

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026